Records containing: Neuroendocrine Tumors
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-10-10A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
-
CLINICAL_TRIALS study record update · 2024-10-01An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2024-09-25Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors
-
CLINICAL_TRIALS study record update · 2024-09-23Clinical-pathological Assessment of Pit-NETs: Data From a Large Multicenter Patients Cohort
-
CLINICAL_TRIALS study record update · 2024-09-19Randomized Phase II Trial in Sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT with 177lu-dotatate
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-09-19A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).
-
CLINICAL_TRIALS study record update · 2024-08-28An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
-
CLINICAL_TRIALS study record update · 2024-08-21Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study
-
CLINICAL_TRIALS study record update · 2024-08-13CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
-
CLINICAL_TRIALS study record update · 2024-08-13"Receptor Radionuclide Therapy With 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR Positive Patients: a Multicenter, Prospective, Phase II Trial"
-
CLINICAL_TRIALS study record update · 2024-08-07Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
-
CLINICAL_TRIALS study record update · 2024-07-19Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
-
CLINICAL_TRIALS study record update · 2024-07-18Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management
-
CLINICAL_TRIALS study record update · 2024-07-16A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
-
CLINICAL_TRIALS study record update · 2024-07-03The Efficacy and Safety of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Gastrointestinal Pancreatic Neuroendocrine Carcinoma: a Real-world Study
-
CLINICAL_TRIALS study record update · 2024-06-25Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2024-06-20Investigation of the Effects of Breakfast or Caffeine Containing Beverages on the Measurement of Plasma Chromogranin A in Patients With Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
-
CLINICAL_TRIALS study record update · 2024-05-14Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients With Cancer
-
CLINICAL_TRIALS study record update · 2024-05-07Observational Study on Clinical, Laboratory, Anatomopathological and Molecular Characteristics and Their Prognostic and Predictive Value in Patients With Neuroendocrine Tumors of the Gastroenteropancreatic Tract and Pulmonary Treated at Fondazione Policlinico Agostino Gemelli (FPG)-IRCCS
-
CLINICAL_TRIALS study record update · 2024-05-06Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
-
CLINICAL_TRIALS study record update · 2024-05-06'5-HIAA in Urine Versus 5-HIAA in Plasma in Patients With a Serotonin Producing Neuroendocrine Tumor'
-
CLINICAL_TRIALS study record update · 2024-05-06Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
-
CLINICAL_TRIALS study record update · 2024-05-06Exploring the Metabolic Profile of Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2024-05-06Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
-
CLINICAL_TRIALS study record update · 2024-04-29A Phase 1/2 Trial Using AZEDRA and LUTATHERA in a Dosimetrically-determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors